Zydus Lifesciences: USFDA Inspection
Zydus Lifesciences (ZYDUSLIFE) filed a disclosure titled "USFDA Inspection". The company is valued at about ₹1.13 lakh crore.
What happened
Zydus Lifesciences (ZYDUSLIFE) filed a disclosure with the exchanges on 13 October 2026 at 08:28 PM titled "USFDA Inspection".
Company snapshot
Zydus Lifesciences is a large-cap company in the Healthcare sector, with a market value of about ₹1.13 lakh crore.
The stock last traded at ₹1,132.5, against a 52-week range of ₹835.5–₹1,232.1 (8.1% below the high).
Before this filing the shares had moved −0.9% over the month and −1.2% over three months. Average daily turnover over the last 20 sessions was about ₹177 crore.
Promoters held 75.01% at the end of Q1 FY27. Foreign institutions owned 6.88% and domestic institutions 11.27%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 6,574 | 1,466.8 | 14.58 |
| Q2 FY26 | 6,123 | 1,258.6 | 12.51 |
| Q3 FY26 | 6,865 | 1,042.1 | 10.36 |
| Q4 FY26 | 7,587 | 1,272.5 | 12.65 |
| Q1 FY27 | 8,017 | 939.8 | 9.35 |
What history shows
This is not the company's first corporate update disclosure: BCEIE has at least 12 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 0.6% on average the next trading day and was down 0.7% on average after five days (10 filings with price data).
Across 5 similar disclosures by other Healthcare companies, shares moved −1.4% on average the next day and −4.9% over five days; 60% of them rose the next day.
Market-wide, 185 corporate update filings with an impact score of 50 or more saw an average next-day move of −0.7%, with 35% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 5 Oct 2026 | Zydus, MSN partner to Launch First Generic of Adempas (Riociguat… | +1.2% | — |
| 1 Oct 2026 | Corporate update | +1.2% | — |
| 1 Oct 2026 | Extension of date of closing | +1.2% | — |
| 28 Sept 2026 | A press release dated September 28, 2026, titled "USFDA inspection… | −4.4% | — |
| 5 Sept 2026 | Corporate update | +2.3% | −0.1% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Zydus Lifesciences, MSN Laboratories Launch First Generic of Adempas in US
- Mankind Pharma, Zydus Lifesciences among top losers, fall up to 3% after Supreme Court asks Centre to...
- ZYDUSLIFE Outlook for the Week
- Zydus Lifesciences Keytruda Biosimilar FYB206 Accepted For USFDA Review
- Zydus Lifesciences zooms 4% after getting USFDA nod for Dapagliflozin Tablets, 5 mg & 10 mg
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.